About this Journal Submit a Manuscript Table of Contents
Infectious Diseases in Obstetrics and Gynecology
Volume 2006 (2006), Article ID 87040, 5 pages
Clinical Study

Attitudes of US Obstetricians Toward a Combined Tetanus-Diphtheria-Acellular Pertussis Vaccine for Adults

1Child Health Evaluation and Research Unit, University of Michigan, Ann Arbor, MI 48109, USA
2Baystate Medical Center, Springfield, MA 01199, USA
3Division of General Internal Medicine, University of Michigan, Ann Arbor, MI 48109, USA
4Gerald R. Ford School of Public Policy, University of Michigan, Ann Arbor, MI 48109, USA
5National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
6Commissioned Corps of the United States Public Health Service, USA

Received 1 June 2006; Accepted 17 August 2006

Copyright © 2006 Sarah J. Clark et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Objective. To describe obstetricians' perspectives related to tetanus-diphtheria-acellular pertussis (Tdap) vaccination of mothers and other adults in close contact with infants. Methods. Mail survey of national random sample of 400 obstetricians . Results. Response rate was 54%. Most respondents would likely recommend Tdap for women during the postpartum hospital stay (78%) or during pregnancy (69%) if a national recommendation was issued. Expected barriers were knowing the date of patients' most recent Td booster (74%) and patient resistance (46%). Most felt that obstetricians have a role in promoting and administering Tdap vaccine to adults other than mothers likely to come in close contact with infants. Conclusion. Obstetricians are likely to agree with the recent provisional US recommendation to administer Tdap to postpartum mothers and other adults expected to come in close contact with infants. Obstetricians would also be likely to support a potential recommendation to administer Tdap during pregnancy. Barriers to adoption of new Tdap vaccine recommendations should be monitored.